Wuxi Biologics Stock Return On Equity
| WXXWY Stock | USD 3.76 0.01 0.27% |
WuXi Biologics fundamentals help investors to digest information that contributes to WuXi Biologics' financial success or failures. It also enables traders to predict the movement of WuXi Pink Sheet. The fundamental analysis module provides a way to measure WuXi Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to WuXi Biologics pink sheet.
WuXi |
WuXi Biologics Company Return On Equity Analysis
WuXi Biologics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current WuXi Biologics Return On Equity | 0.12 |
Most of WuXi Biologics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, WuXi Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, WuXi Biologics has a Return On Equity of 0.123. This is 100.51% lower than that of the Healthcare sector and 100.34% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 139.68% lower than that of the firm.
WuXi Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses WuXi Biologics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of WuXi Biologics could also be used in its relative valuation, which is a method of valuing WuXi Biologics by comparing valuation metrics of similar companies.WuXi Biologics is currently under evaluation in return on equity category among its peers.
WuXi Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 29.3 B | |||
| Shares Outstanding | 2.11 B | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 97.10 X | |||
| Price To Book | 6.03 X | |||
| Price To Sales | 2.03 X | |||
| Revenue | 10.29 B | |||
| Gross Profit | 4.83 B | |||
| EBITDA | 4.39 B | |||
| Net Income | 3.39 B | |||
| Cash And Equivalents | 9.86 B | |||
| Cash Per Share | 4.72 X | |||
| Total Debt | 640.51 M | |||
| Debt To Equity | 0.12 % | |||
| Current Ratio | 2.30 X | |||
| Book Value Per Share | 16.51 X | |||
| Cash Flow From Operations | 3.43 B | |||
| Earnings Per Share | 0.27 X | |||
| Price To Earnings To Growth | 0.81 X | |||
| Number Of Employees | 10.59 K | |||
| Beta | 1.09 | |||
| Market Capitalization | 34.7 B | |||
| Total Asset | 44.03 B | |||
| Z Score | 32.4 | |||
| Net Asset | 44.03 B |
About WuXi Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze WuXi Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of WuXi Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of WuXi Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for WuXi Pink Sheet Analysis
When running WuXi Biologics' price analysis, check to measure WuXi Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WuXi Biologics is operating at the current time. Most of WuXi Biologics' value examination focuses on studying past and present price action to predict the probability of WuXi Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WuXi Biologics' price. Additionally, you may evaluate how the addition of WuXi Biologics to your portfolios can decrease your overall portfolio volatility.